Thomas Wooldridge, MD
Nephrology · Tupelo, MSNPI 1518937044
Payments from drug & device makers
Across 727 payments — averaging $2245.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$670K
- GSK$383K
- CSL Behring$271K
- Akebia Therapeutics Inc$146K
- Alnylam Pharmaceuticals Inc.$31K
- AstraZeneca$31K
- plus $100K from 29 others
Across 3 payments — averaging $2706.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Co., Ltd.$8K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 17 | $669,746 |
| GSK | 57 | $382,692 |
| CSL Behring | 50 | $270,960 |
| Akebia Therapeutics Inc | 158 | $146,289 |
| Alnylam Pharmaceuticals Inc. | 6 | $31,373 |
| AstraZeneca | 70 | $31,326 |
| Otsuka Pharmaceutical Co., Ltd. | 15 | $30,450 |
| Bayer | 69 | $29,494 |
| Astrazeneca UK Limited | 1 | $18,100 |
| Biogen | 2 | $8,663 |
| Ardelyx, Inc. | 18 | $7,894 |
| Travere Therapeutics, Inc. | 26 | $952 |
| Fresenius USA Marketing, Inc. | 47 | $892 |
| Otsuka America Pharmaceutical, Inc. | 41 | $840 |
| Mallinckrodt Hospital Products Inc. | 32 | $675 |
| Vifor Pharma, Inc. | 21 | $374 |
| Novartis | 15 | $335 |
| Amgen | 18 | $324 |
| OPKO Pharmaceuticals, LLC | 18 | $288 |
| Daiichi Sankyo Inc. | 7 | $140 |
| Aurinia Pharma U.S., Inc. | 6 | $138 |
| ANI Pharmaceuticals, Inc. | 5 | $87 |
| Calliditas Therapeutics US Inc. | 4 | $80 |
| Sunovion Pharmaceuticals Inc. | 4 | $60 |
| Novo Nordisk | 4 | $56 |
| Boehringer Ingelheim | 3 | $47 |
| Mallinckrodt Enterprises LLC | 3 | $43 |
| Lilly USA, LLC | 2 | $34 |
| AMAG Pharmaceuticals, Inc. | 2 | $29 |
| Baxter Healthcare | 1 | $25 |
| Renalytix AI, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Sanofi | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
How this compares
$1,632,511 in reported general payments places this provider in the 95th percentile of 105 nephrology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Tupelo
- Marcus BrittonTupelo$339K
- John Martin LeeTupelo$6K
- Morris HamiltonTupelo$6K
- John ElliottTupelo$5K
- Christopher MillerTupelo$4K
- Tzonko MilevTupelo$4K
- Amita MaibamTupelo$4K
- Calvin BakerTupelo$2K
- Shanti ParkashTupelo$2K
- Richard MillerBrookhaven$772K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.